Dual role for miR-34a in the control of early progenitor proliferation and commitment in the mammary gland and in breast cancer.


Journal

Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562

Informations de publication

Date de publication:
01 2019
Historique:
received: 20 11 2017
accepted: 19 06 2018
revised: 06 06 2018
pubmed: 11 8 2018
medline: 23 4 2019
entrez: 11 8 2018
Statut: ppublish

Résumé

The role of the tumour-suppressor miR-34 family in breast physiology and in mammary stem cells (MaSCs) is largely unknown. Here, we revealed that miR-34 family, and miR-34a in particular, is implicated in mammary epithelium homoeostasis. Expression of miR-34a occurs upon luminal commitment and differentiation and serves to inhibit the expansion of the pool of MaSCs and early progenitor cells, likely in a p53-independent fashion. Mutant mice (miR34-KO) and loss-of-function approaches revealed two separate functions of miR-34a, controlling both proliferation and fate commitment in mammary progenitors by modulating several pathways involved in epithelial cell plasticity and luminal-to-basal conversion. In particular, miR-34a acts as endogenous inhibitor of the Wnt/beta-catenin signalling pathway, targeting up to nine upstream regulators at the same time, thus modulating the expansion of the MaSCs/early progenitor pool. These multiple roles of miR-34a are maintained in a model of human breast cancer, in which chronic expression of miR-34a in triple-negative mesenchymal-like cells (enriched in cancer stem cells-CSCs) could promote a luminal-like differentiation programme, restrict the CSC pool, and inhibit tumour propagation. Hence, activation of miR-34a-dependent programmes could provide a therapeutic opportunity for the subset of breast cancers, which are rich in CSCs and respond poorly to conventional therapies.

Identifiants

pubmed: 30093634
doi: 10.1038/s41388-018-0445-3
pii: 10.1038/s41388-018-0445-3
pmc: PMC6336680
doi:

Substances chimiques

MIRN34 microRNA, human 0
MIRN34a microRNA, mouse 0
MicroRNAs 0
RNA, Neoplasm 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

360-374

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA149707
Pays : United States
Organisme : Fondazione Cariplo (Cariplo Foundation)
ID : 2015-0590
Pays : International
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : IG18774
Pays : International

Commentaires et corrections

Type : ErratumIn

Références

Oncogene. 2000 Feb 21;19(8):1002-9
pubmed: 10713683
Genes Dev. 2000 Mar 15;14(6):650-4
pubmed: 10733525
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
Nature. 2006 Feb 23;439(7079):993-7
pubmed: 16395311
Nature. 2006 Jan 5;439(7072):84-8
pubmed: 16397499
Dev Biol. 2006 May 15;293(2):414-25
pubmed: 16545360
J Biol Chem. 2006 Nov 17;281(46):35081-7
pubmed: 16973609
Nat Cell Biol. 2006 Dec;8(12):1398-406
pubmed: 17072303
Cancer Cell. 2007 Mar;11(3):259-73
pubmed: 17349583
Nature. 2007 Jun 28;447(7148):1130-4
pubmed: 17554337
Nat Biotechnol. 2007 Dec;25(12):1457-67
pubmed: 18026085
Cell. 2007 Dec 14;131(6):1109-23
pubmed: 18083101
Breast Cancer Res. 2008;10(2):R25
pubmed: 18366788
Cell Stem Cell. 2007 Nov;1(5):555-67
pubmed: 18371393
Nat Rev Mol Cell Biol. 2008 May;9(5):355-66
pubmed: 18431399
Cell Cycle. 2008 Aug 15;7(16):2591-600
pubmed: 18719384
Cancer Res. 2008 Dec 15;68(24):10094-104
pubmed: 19074875
Nat Rev Mol Cell Biol. 2009 Feb;10(2):116-25
pubmed: 19165214
Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3207-12
pubmed: 19202062
Cell. 2009 Aug 7;138(3):592-603
pubmed: 19665978
Cell. 2009 Sep 18;138(6):1083-95
pubmed: 19766563
Cell. 2010 Jan 8;140(1):62-73
pubmed: 20074520
Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6334-9
pubmed: 20308559
Breast Cancer Res. 2010;12(2):R21
pubmed: 20346151
J Clin Oncol. 2010 Sep 1;28(25):4006-12
pubmed: 20498387
Nat Med. 2011 Feb;17(2):211-5
pubmed: 21240262
Nat Cell Biol. 2011 Mar;13(3):317-23
pubmed: 21336307
PLoS One. 2011;6(8):e21396
pubmed: 21857907
Nat Cell Biol. 2011 Oct 23;13(11):1353-60
pubmed: 22020437
Sci Signal. 2011 Nov 01;4(197):ra71
pubmed: 22045851
Nature. 2012 Feb 15;482(7385):347-55
pubmed: 22337054
Cell. 2012 Mar 2;148(5):1015-28
pubmed: 22385965
Front Genet. 2012 Jul 02;3:120
pubmed: 22783274
PLoS Genet. 2012;8(7):e1002797
pubmed: 22844244
Cell Stem Cell. 2012 Sep 7;11(3):387-400
pubmed: 22863533
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
J Cell Biol. 2012 Oct 1;199(1):77-95
pubmed: 23027903
Nature. 2013 Mar 7;495(7439):107-10
pubmed: 23426265
Cell Stem Cell. 2013 May 2;12(5):602-15
pubmed: 23642368
Sci Rep. 2013;3:2687
pubmed: 24045437
J Mol Cell Biol. 2014 Jun;6(3):214-30
pubmed: 24815299
Nature. 2014 Jun 5;510(7503):115-20
pubmed: 24899310
Nature. 2014 Aug 28;512(7515):431-5
pubmed: 25043055
Cancer Res. 2014 Dec 15;74(24):7573-82
pubmed: 25368020
Cancer Sci. 2015 Jun;106(6):700-8
pubmed: 25783790
Tumour Biol. 2017 May;39(5):1010428317701652
pubmed: 28468587
Cell. 1982 Nov;31(1):99-109
pubmed: 6297757

Auteurs

Paola Bonetti (P)

Center for Genomic Science of IIT@SEMM, Istituto Italiano di Tecnologia (IIT), 20139, Milan, Italy. paola.bonetti@iit.it.

Montserrat Climent (M)

Center for Genomic Science of IIT@SEMM, Istituto Italiano di Tecnologia (IIT), 20139, Milan, Italy.

Fabiana Panebianco (F)

Center for Genomic Science of IIT@SEMM, Istituto Italiano di Tecnologia (IIT), 20139, Milan, Italy.

Chiara Tordonato (C)

IFOM, the FIRC Institute for Molecular Oncology Foundation, 20139, Milan, Italy.

Angela Santoro (A)

Department of Experimental Oncology, European Institute of Oncology (IEO), 20100, Milan, Italy.

Matteo Jacopo Marzi (MJ)

Center for Genomic Science of IIT@SEMM, Istituto Italiano di Tecnologia (IIT), 20139, Milan, Italy.

Pier Giuseppe Pelicci (PG)

Department of Experimental Oncology, European Institute of Oncology (IEO), 20100, Milan, Italy.
Dipartimento di Scienze della Salute, Università degli Studi di Milano, 20100, Milan, Italy.

Andrea Ventura (A)

Memorial Sloan-Kettering Cancer Center (MSKCC), New York, USA.

Francesco Nicassio (F)

Center for Genomic Science of IIT@SEMM, Istituto Italiano di Tecnologia (IIT), 20139, Milan, Italy. francesco.nicassio@iit.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH